SOUTH SAN FRANCISCO, Calif., Aug. 8, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it will host a teleconference and webcast with management to provide a general business overview, as well as to discuss its second quarter 2013 financial results on Wednesday, August 14, 2013 at 4:30 p.m. EDT (1:30 p.m. PDT.) Financial results for the quarter ended June 30, 2013 will be released after market close on August 14, 2013. To access the live conference call, dial 877-847-7188 U.S. or 408-427-3787 International and use the conference ID# 21769835. Individuals may access the live audio webcast at http://investors.hyperiontx.com/events.cfm . A replay of the webcast will be available on the Company's website for 30 days following the live event. About Hyperion Therapeutics Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases and hepatology. The company's first commercial product, Ravicti® (glycerol phenylbutyrate) Oral Liquid, was approved in February 2013 and is currently being marketed in the United States. The company also owns and markets BUPHENYL® (sodium phenylbutyrate) Tablets and Powder worldwide. For more information, please visit www.hyperiontx.com.
CONTACT: Sylvia Wheeler, Investor Relations (650) 794-7834